Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.36 USD | +1.11% | +0.16% | -27.48% |
Mar. 27 | MiMedx Group Says FDA Affirms Axiofill Falls Short of Regulatory Standards for Tissue-Based Products | MT |
Mar. 27 | MiMedx Says FDA Still Won't Budge on Axiofill Designation, Files Lawsuit | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-27.48% | 935M | |
-19.40% | 129M | |
+6.59% | 58.57M | |
-17.68% | 60.24M | |
+8.40% | 61.54M | |
-2.40% | 50.41M |
- Stock Market
- Equities
- MDXG Stock
- News MiMedx Group, Inc.
- MiMedx : Northland Capital Reinstates MiMedx Group at Outperform with $23 Price Target